bolic side effects such as skeletal muscle (SM) atrophy, adipose tissue (AT) mass redistribution, bone mass loss, glucose intolerance, and decrease in insulin sensitivity, which causes or aggravates diabetes.
Most effects of GCs are mediated by the intracellular GC receptor [GR (NR3C1)], which belongs to the nuclear receptor superfamily. GR is ubiquitously expressed from a single locus that gives rise to many different transcript variants. Only GR␣ is transactivated by GCs and binds to glucocorticoid response elements (GRE) as homodimers, which leads to positive and negative changes in gene transcription (13) .
Comprehensive analyses of the gene expression patterns and regulatory networks involved in tissue development, remodeling, and secretion are prerequisites to completely understand the effects of GCs on various tissues and whole body homeostasis (24) . Such analyses also may help in the development of inflammatory/immunomodulatory therapeutic agents devoid of side-effects. No studies have investigated the in vivo shortterm corticosteroid effects at the molecular level in humans.
The present study aims at improving the molecular understanding of the impact of GCs on two tissue targets of the side-effects of corticosteroids, SM and AT. A short-term dexamethasone treatment was investigated in healthy human volunteers to avoid the confounding effects of long-term fat redistribution and SM atrophy. (19 -44 yr) were recruited at the Nutrition and Toxicology Research Institute of Maastricht, Maastricht University (Maastricht, The Netherlands). The subjects were on their usual diet before the study. None were engaged in heavy physical activity training. Their characteristics are presented in Table 1 . The protocol was approved by the Ethics Committee of the Maastricht University Medical Centre. All subjects gave written informed consent.
MATERIALS AND METHODS

Subjects. Fifteen healthy Caucasian males
Study design. Dexamethasone (Decadron 0.5 mg, Merck Sharp Dohm) was provided 4 mg per day in 0.5 mg tablets during 4 days. The subjects were instructed to continue with their usual level of physical activity as well as eating habits during the study. The same investigations were performed before and after treatment as follows. After an overnight fast and a 45-min resting period, oxygen consumption (VO 2) and carbon dioxide production (VCO2) were monitored over 60 min using a ventilated hood measurement system (Omnical, Mijnhardt, Bunnik, The Netherlands). Respiratory quotient was derived from VO 2 and VCO2 using indirect calorimetry. Thereafter blood samples were drawn for determinations of hormonal and metabolic parameters. A percutaneous biopsy of the vastus lateralis muscle and a needle subcutaneous fat biopsy from the abdominal region lateral to the umbilicus were obtained as previously described (5, 43) . The second biopsy was taken from the contralateral abdominal region and leg. Body composition was assessed by single frequency bioimpedance spectrometry at 50 kHz (41) . A Xitron 4000B was used for bioimpedance analyses, using a tetrapolar arrangement of gel electrodes placed on the hand, wrist, ankle, and foot of the right side of the body. Fat free mass (FFM) was calculated using a prediction equation (FFM ϭ 0.756 S 2 /R ϩ 0.11 W ϩ 0.107 Xc Ϫ 5.463, where S is stature, R is resistance, W is weight, and Xc is reactance). The 24 h urine samples were collected for all subjects before treatment and on day 4 .
Plasma biochemical determinations. Blood glucose was assayed using the glucose oxidase technique (Biotrol, Paris, France). Serum insulin was measured using EIA kits from Mercodia (Uppsala, Sweden). Atrial natriuretic peptide (ANP) levels were determined using radioimmunoassay kits from Peninsula Laboratories (San Carlos, CA), IL6 and ultrasensitive C reactive protein (CRPus) was measured with Quantikine ELISA tests (R&D system). Human serum amyloid A (SAA) was measured using ELISA kit from US Biological (Swampscott, MA). Other parameters were determined using standard clinical biochemistry methods.
Total RNA preparation. Total RNA from frozen biopsies were prepared as previously described (5, 43) . Total RNA concentration and quality were checked using the Agilent 2100 Bioanalyzer and RNA 6000 labChip Kit (Agilent Technologies, Massy, France). A flow chart of the sample processing and decision tree is presented in Fig. 1 .
Probe labeling and microarray analysis. Target RNA was generated from 500 ng of total RNA with the Agilent low RNA input amplification kit (Agilent Technologies). A Nanodrop quality check led to the exclusion of one SM labeled sample and nine AT labeled samples. Transcriptome analyses were conducted before and after the 4-day dexamethasone treatment, using a dye swap design and whole genome 4 ϫ 44k oligonucleotide arrays (Agilent Technologies). Data acquisition was performed with an InnoScan 700 scanner (Innopsys, Carbonne, France), and images were processed with Mapix software (Innopsys). Hybridization was quality checked using control spikes. Outlier replicates and spots with a signal-to-noise ratio Ͻ2 on both red and green channels were eliminated from the analyses, resulting in 22,404 (SM) and 22,710 (AT) exploitable spots. Mean log ratios were calculated from paired duplicates before normalization. Raw data were normalized with a global Loess procedure and filtered with the R package LIMMA (Bioconductor). Principal component analysis was used to check that all microarray experiments provided consistent data. In the end, we performed the statistical analysis using microarray data from 10 and four different subjects for SM and AT, respectively. These subjects did not differ from the whole group regarding baseline characteristics and change in plasma parameters (data not shown). Microarray data were analyzed using the one-class Significance Analysis of Microarray procedure (40) . To find the relation between gene expression and clinical outcomes, partial least square regression (PLS-R) analysis was done using SIMCA-Pϩ version 12 (Umetrics, Kinnelon, NJ) (46) . Functional analysis was done using Ingenuity Pathway Analysis (IPA) version 7.5 (4). Ingenuity's Pathways Knowledge Base was seeded with the adipose tissue and skeletal muscle gene symbols together with the array mean fold change of the differentially expressed genes. A Benjamini-Hochberg multiple testing correction P value was applied to the 2,217 (AT) and 1,815 (SM) eligible gene symbols of the dataset. Data were considered significant for P value Ͻ 0.05. Gene set enrichment analysis (GSEA) version 2.04 (35) was performed using predefined curated gene sets in the Molecular Signatures Database, MSigDB (http://www.broad.mit.edu/ gsea/), and in-house (5, 7, 26, 43) gene sets. GSEA was performed on gene lists ranked by level of dexamethasone-induced gene expression changes. Gene set size filters (min. ϭ 10, max. ϭ 500) resulted in filtering out 1,127/1,920 gene sets. The remaining 793 gene sets were used in the analysis. Correlations to the predefined curated gene sets were analyzed using the GSEA preranked tool with 1,000 permutations. Only gene sets with FWER P value Յ 0.01 were considered significant. Prediction of nonclassical protein secretion (Secretome P 2.0) (1) and prediction of signal peptide cleavage sites (SignalP 3.0) (2) were assessed using the CBS Prediction Servers (http://www. cbs.dtu.dk/services/).
Real-time quantitative PCR. Reverse transcription (RT) was performed using 1 g of total RNA for each sample as previously described (43) . Primers were designed using Primer express software or we used premade gene expression assays (Applied Biosystems, Foster City, CA). 18S (Taqman Control Assays, Applied Biosystems) mRNA concentration was used to normalize gene expression. Primer sequences are available upon request.
Gene promoter analysis. To identify transcription factors that may have contributed to the effect of dexamethasone on the regulation of gene expression, we analyzed genomic DNA sequences encompassing gene transcription start sites (tss) for genes with Ͼ1.5-fold change during dexamethasone treatment. Regions included 5,000 bp upstream and 2,000 bp downstream of each gene tss defined below. The SQL-dumps from the human refFlat and tfbsConsSites tables were downloaded from the UCSC ftp site (18) . The refFlat table contains the locations and orientations of all RefSeq transcripts on the genome and tfbsConsSites table contains the locations of hits to Transfac matrices that are conserved between human, mouse, and rat (HMR). The refFlat table data was processed so that all overlapping transcripts with the same gene symbol were reduced to a single transcript by selecting the transcript with the longest spliced length (longFlat). Then longFlat was used in conjunction with tfbsConsSites to partition all HMR conserved TFBS data into gene-centric subsets. Each set of input gene symbols led to the generation of four numerical counts for each transfac matrix (a-d, below) and the Fisher's exact test was applied to generate P values: a, number of genes from the input set that had the factor in the region; b, number of genes from the input set that did not have the factor in the region; c, number of genes from the reference set that had the factor in the region; d, number of genes from the reference set that did not have the factor in the region. Fisher's exact test (n ϭ a ϩ b ϩ c ϩ d):
Conventional statistical analysis. Statistical analysis was performed using SPSS for Windows 17.0 (SPSS, Chicago, IL). Results from nonparametric paired Wilcoxon test and Pearson's correlation were considered significant if P Ͻ 0.05.
Microarray data set. All data are accessible through the NCBI's Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) series accession number GSE17992.
RESULTS
Effects of the dexamethasone treatment on metabolic and plasma parameters.
Characteristics of the healthy male volunteers enrolled in the protocol are presented in Table 1 . As expected, the 4-day dexamethasone treatment (4 mg/day) resulted in a disappearance in urinary cortisol from all subjects with one exception, who was discarded from the study due to lack of compliance ( Fig. 1) . Table 2 presents plasma parameters from the 14 remaining subjects before and after the 4-day treatment. CRP was decreased by 70% and ANP levels were increased. Plasma insulin increased while glycemia remained constant, and the insulin resistance index HOMA-IR doubled. There was no change in the metabolic and lipolytic index, resting metabolic rate respiratory quotient and glycerol, respectively. Also body weight was stable over this period.
Changes in skeletal muscle and adipose tissue gene expression profiles induced by dexamethasone. Quantity and quality of total RNA were obtained, before and after dexamethasone treatment, for samples from 13 (SM) and 5 (AT) out of 14 subjects. Figure 1 shows a flow-chart of the study. Stringent quality control at each step of the gene expression profiling resulted in the retention of data from 10 and 4 subjects for SM and AT, respectively. Tables S1 and S2) . 1 Changes in mRNA levels of 24 genes (both up-and downregulated) were verified using RT-qPCR to validate the microarray data (Table 3) . Only 477 dexamethasone target genes were common to SM and AT with 290 upregulated and 187 downregulated. In SM, 2,042 genes (1,258 up-and 784 downregulated) were specifically regulated and 3,016 genes (1,483 up-and 1,533 downregulated) showed changes in expression level in AT only (data not shown).
In SM, the statistical procedure resulted in 1,609 upregulated and 1,019 downregulated transcripts, including 183 genes (155 up and 28 down) with a Ͼ1.5-fold change. Despite the increase in plasma insulin there was very little overlap (63 up and 1 down) with genes already described as regulated by insulin in SM of healthy volunteers (33) . A small subset of differentially expressed genes were also regulated, in human SM, by another nuclear receptor ligand, tri-iodo thyronine (35 up and 0 down) (7), or the other stress hormone adrenaline (69 up and 32 down) (43) , indicating that most of the regulations observed in SM were dexamethasone-specific. As indicated in Fig. 2 , the top ranking IPA list was "positive acute phase response proteins" with 90% of the genes upregulated. The list of genes are displayed in Table 4 . The IPA ontology also selected the lists "hypoxia-inducible factor signaling" and "oxidative stress mediated by Nrf2," which consisted of 79 and 69% of upregulated genes, respectively. This is to be related to the observation that nine metallothionein (MT) isoforms that are antioxidant pro- 1 The online version of this article contains supplemental material. teins were upregulated in SM during dexamethasone treatment (Supplementary Table S1 ). Figure 3 displays a core network with SM inflammatory signature that is mainly composed of upregulated genes and centered on the TNF receptor and 12 related molecules.
Because numerous genes had a mean fold change Ͻ1.5 we also used the GSEA method. This revealed two upregulated and three downregulated gene sets within the dexamethasoneregulated genes in SM (Table 5 ). Figure 4 outlines the most significant gene set, "HOUSTIS_ROS," which contains genes known to modulate reactive oxygen species (ROS) or whose expression changes in response to ROS (16) . The enrichment of this set with the upregulated genes shows a response to oxidative stress. The downregulated genes enriched a "CELL_ ADHESION_MOLECULES" gene set (Fig. 4) . This is to be associated with the remodeling effect of cortisol treatment on skeletal muscle tissue. The "ANTIGEN_PROCESSING_AND_ PRESENTATION" gene set is mainly composed of major histocompatibility complex class II molecules, which are related to T cell activation and have been described as located to endothelial cells of skeletal muscle from healthy donors (9) .
In AT, we found 1,771 upregulated and 1,718 downregulated transcripts (Supplementary Table S2 ) and identified 1,148 genes that had Ͼ1.5-fold change after dexamethasone treatment in AT (765 up-and 383 downregulated). IPA selected the following gene lists enriched with upregulated genes: "oxidative stress," "NF-B signaling pathway," "mechanism of gene regulation by peroxisome proliferators via PPAR␣," and "positive acute phase response proteins" (Fig. 2) . Of the genes from the "positive acute phase response" list 78% were upregulated ( Table 4 ). The "cholesterol biosynthesis" and "mitochondrial dysfunction" lists contained a vast proportion of downregulated genes. The AT inflammatory pattern is illustrated in Fig.  3 . This network encompasses many upregulated secreted factors and C/EBP␣ as main focus. GSEA was applied to the AT data, and representative results are displayed in Tables 4 and 5 . All three sets fitting with the AT downregulated genes are related to mitochondrial energy metabolism. Figure 4 illustrates the most representative gene sets enriched in the AT samples. There was a large number of sets that correlated with Ingenuity's Pathways Knowledge Base was seeded with the adipose tissue and skeletal muscle gene symbols and the array mean fold change of the differentially expressed genes. A Benjamini-Hochberg multiple testing correction P value was applied. The positive acute-phase response protein list is originally composed of 32 molecules. The skeletal muscle analysis sorted 10 genes among 32, and the adipose tissue analysis sorted 9 genes among 32. Boldface indicates downregulated genes. the upregulated genes including "AT_LCD_UP " that is composed of genes with increased expression level during energy restriction by low-calorie diet (Fig. 4) , including the glutathione peroxidase GPX3 as top-ranking gene.
For more insight into the transcription factors that coordinate the observed changes in gene expression, we used data from a genome-wide transcription factor binding site conservation analysis, known as the TFBS Conserved track within the UCSC Genome Browser (see MATERIALS AND METHODS). The results of this analysis are presented in Table 6 . The most statistically significant binding site turned out to be for NR3C1 (GR_Q6) for the dexamethasone-downregulated genes, a sequence that was not enriched in the upregulated gene set. Interestingly, both nuclear factor-kappa B (NF-B), the major transcription factor of immune response, and CCAAT/ enhancer binding protein (C/EBP), C/EBP␣ and C/EBP␤ were among the most frequently occurring matrices in the upregulated gene set. The key factor of skeletal muscle differentiation MyoD was also significantly overrepresented in the set of upregulated genes.
Gene expression and plasma factors relationship. In an attempt to investigate a potential link between inflammatory gene expression and circulating factors, we measured circulating acute-phase SAA and IL6. SAA mRNA levels were upregulated in both tissues (2.6-and 1.8-fold for SAA1 and -2 isoforms, respectively, in SM and 1.7-fold for SAA4 in AT), and transcripts for IL6 increased in AT only. The mean plasma SAA fold change was 3.4 Ϯ 0.7 (n ϭ 14), while there was no significant change in circulating IL6 (data not shown).
There was no significant correlation between changes in HOMA-IR and variations in plasma SAA, CRP, or ANP. The potential contribution of gene expression changes into the worsening in insulin sensitivity was assessed using PLS-R. The most significant model was found with a list of 15 SM genes (Fig. 5) . However, no representative biological function was found in this list that contains four DNA binding proteins (GTF2F1, HNRPDL, ZNF473, and SRRM1) and only one putative secreted protein (CCDC47), which is expressed in response to ER overload (29) .
DISCUSSION
GCs are broadly used at various doses as anti-inflammatory, immunomodulatory, and cytotoxic drugs. Because they are often prescribed for long-term treatments, the major side-effect of such therapy is that it induces profound bone, SM, and AT remodeling. In addition, GCs usually decrease glucose toler- ance, sometimes decrease insulin sensitivity (45) , and blunt both basal and stimulated muscle glucose transport (42) .
Although the molecular mechanisms of GC-induced regulation of transcription have been studied in detail (13) , the global molecular networks on specific tissues are only partially described in humans. In the present study, we focused on SM and AT, two important tissues implicated as much as in metabolic than in inflammatory regulations (5, 43) , during a short-term treatment using a corticotrope axis blocking dose of dexamethasone. A 4-day period was chosen to avoid changes in body weight and other related parameters due to changes in food intake. None of the body mass-related variables differ over this period of treatment.
Tissue remodeling. High levels of corticosteroids are frequently associated with loss of muscle mass and fat redistribution. Microarray analyses of skeletal muscle atrophy during short-term dexamethasone treatment has been described in rats (20) and bull skeletal muscle with an overrepresentation of Wnt and also cytokine signaling (6) . Here, as support for the ubiquitous developmental impact of dexamethasone, the inhibitor of Wnt signaling SFRP4, a key regulator of both adipogenesis (32) and myogenesis (34) , was downregulated in both tissues. We observed enrichment for signatures of the adipogenic transcription factor C/EBP␣ and C/EBP␤ in the set of upregulated genes (44) . C/EBP␣ mRNA levels increased in SM and AT. C/EBP␤ may also regulate multiple genes in the ubiquitin proteasome proteolytic system (30) . Of the genes encoding proteins of the ubiquitin proteasome system, 85 and 65% were upregulated in SM and AT, respectively. These genes represented a minor fraction of the genes involved in tissue morphology including proteolytic, adhesion, and cell growth processes. GSEA was performed on gene lists ranked by level of dexamethasone-induced gene expression changes. Gene set size filters (min ϭ 10, max ϭ 500) resulted in filtering out 1,127/1,920 gene sets. The remaining 793 gene sets were used in the analysis. Correlations to the predefined curated gene sets were analyzed using the GSEA preranked tool with 1,000 permutations. Only gene sets with FWER P value Յ0.01 were considered significant. GSEA, gene set enrichment analysis; NES, normalized enrichment score; FDR, false discovery rate; FWER, family-wise error rate; AT, adipose tissue; LCD, low calorie diet.
Response to stress. The most striking effect of dexamethasone observed here is the global signature for a response to stress in both tissues. The common dexamethasone target genes encode acute-phase proteins involved in innate immunity, including SAA, C1q, ficolins, and lectins. As previously reported in human SM, expression of the mitochondrial enzyme monoamine oxidase (MAOA) was increased (25) . MAOA activity is associated with adverse effects in various cell types, mediated in part by hydrogen peroxide, which plays a critical role in ROS production and cell death (39) . Increased expression of MAOA may account for the toxic effects of GCs on both tissues. A link between ROS and insulin resistance has also been shown (16) , and free radicals may regulate SM functions (36) . In AT, the most downregulated gene was 11␤-hydroxysteroid dehydrogenase type 1 (HSD11B1), which encodes the enzyme responsible for local active cortisol production. This might be interpreted as a local negative feedback response to the rise in corticosteroid. GCs are critical regulators of immune response and metabolism during stress and conditions that can be associated with stress such as starvation. The AT response to dexamethasone exhibited a common pattern to energy restriction as indicated the decrease in OXPHOS function and upregulation of low calorie diet-responsive genes. We previously observed a downregulation of HSD11B1 mRNA in AT after weight loss (5) . In this tissue, oxidative stress was one of the most enriched biological functions. Along Fig. 4 . GSEA of gene sets for dexamethasone-responsive genes. The enrichment score (ES) profile (top) records the cumulative score of the gene ranks from the target gene set. If a majority of gene ranks from the target gene set are high (i.e., toward the start of ranking) compared with the rest of genes, the cumulative ranking score (profile) will have a high peak, suggesting a significant enrichment of this gene set. The horizontal line indicates the zero value for the ES. The x-axis lists all the genes ranked based on their associations with phenotype. The vertical bars (middle) indicate candidate genes in the target gene set. Vertical notches on the spectral index bar plot (bottom) represent members of the gene set that were detected in our study, each of which contribute to the running sum statistic in proportion to their ranked list metrics value. The "leading-edge" members of the gene set, which drive the ES, are represented by bold notches at bottom. Horizontal bars in graded color from left to right represent mRNA targets ranked from high expression in dexamethasone effect. ROS, reactive oxygen species; AT, adipose tissue; LCD, low-calorie diet.
with the acute-phase proteins, immunity and defense pathways contained mostly upregulated genes, including leukotrieneproducing mediators of inflammation and host defense molecules. In SM, besides the increased expression of oxidative stress genes, numerous MT genes were upregulated. MTs are potent antioxidant proteins that protect cells and tissues from oxidative stress. Combined with the upregulation of GPX3 and superoxide dismutase (SOD2), overexpression of a large panel of MTs may reflect a response to corticosteroid-induced oxidative stress to prevent a subsequent catabolism or insulinresistant state.
Inflammatory and immune responses. SM and AT presented a significant enrichment in the positive acute-phase response group. Both tissues also showed an increase in the expression of the acute-phase SAA. Acute-phase proteins such as CRP and SAA are released by the liver during both innate and adaptive immune responses and have proven to be useful biomarkers of systemic disease activity/severity. SAA is also expressed in the adipocytes, and SAA4 was upregulated in AT in the present study. SAA1 and SAA2 were also overexpressed in SM. A high correlation of plasma SAA with AT gene expression has been described (31) . In the present study, we found an expected drop in the acute-phase protein CRP, while the anti-inflammatory ANP and the plasma SAA increased. Two UCSC Genome Browser database tables were used to obtain sets of transcription factor binding sites associated with transcription start sites of genes from the RefSeq database. The refFlat table contains the genomic coordinates of all RefSeq transcripts and was used to demarcate regions 5 kb upstream and 2 kb downstream of all transcripts. The tfbsConsSites table was intersected with the set of upstream regions to create sets of potential transcriptional regulators for each gene. This table was used as it is the result of a human/mouse/rat conservation analysis performed using the TRANSFAC database. For each set of input genes, the above data were used to perform a Fisher's exact test in order to determine if any transcription factor matrices were overrepresented in the input set with respect to the reference set (all transcripts minus the input set). The GC induced upregulation of ANP has been described in rat myocytes (28) . SAA has been shown elevated after GCs treatments in nonhepatic cell types (19, 21, 38, 47) and 3T3-L1 adipose cells, which also exhibited an increased IL6 mRNA level (10) . Here, besides sets of downregulated chemokines, a large group of proinflammatory factors, including interleukins and chemokines, were overexpressed, especially in AT. Genes encoding receptors for chemokines and interleukins or signal transduction were also upregulated. Other dexamethasone-induced genes include proinflammatory adipokines (leptin and PBEF1/ visfatin), leukotriene-producing mediators of inflammation (ALOX5 and ALOX5AP), and host defense molecules (DEFA3, DEFA4, TRA SU). RARRES, which encodes a recently discovered anti-inflammatory chemokine called chemerin, were downregulated. Of note, the increase in C/EBP␤, which has recently been shown to suppress TNF-␣-induced activation of NF-B in renal mesangial cells (14) , might explain the unexpected proinflammatory impact of dexamethasone on SM and AT.
Association with metabolic features. SM and AT secretory and metabolic activity are important for maintaining body homeostasis as they release factors that regulate various systemic processes including insulin sensitivity. Within 4 days the dexamethasone treatment decreased insulin sensitivity. Several mediators and mechanisms have been proposed to cause insulin resistance, including defective lipid metabolism, endoplasmic reticulum stress, and oxidative stress. Chronic systemic elevation of SAA has been linked to metabolic syndrome and has recently been show to correlate with insulin resistance in humans (48) . Despite the lack of a clear-cut relationship between changes in gene expression or plasma SAA and HOMA-IR in the present study, some lines of evidence support the decrease in systemic insulin sensitivity. The link between the rise in plasma SAA and the worsening in insulin sensitivity may be indirect. Further in vitro investigations might be useful to decipher the regulation of SAA and their putative contribution to the worsened insulin sensitivity in this context. Some dexamethasone-sensitive genes exhibit regulation in line with the decrease in insulin sensitivity. Visfatin and leptin, which have also been described as related to insulin sensitivity (11, 17) , and ADIPOR1, a receptor for the insulin-sensitizing adiponectin (22) , were found to be overexpressed in AT. In addition, chemerin, which potentiates the effect of insulin on glucose uptake in the 3T3-L1 adipose cell line (37), was downregulated. Accordingly, apelin, which stimulates glucose uptake (8) , and the transcriptional coactivator PGC-1␣, which plays a major role in energy metabolism and insulin resistance (26) , were downregulated in SM. PGC-1␣ is a key coactivator for oxidative phosphorylation and modulates gene expression that affects glucose and fat metabolism in a number of insulinsensitive tissues (27) . Numerous genes encoding proteins of the mitochondrial NADH dehydrogenase complex and cytochrome c oxidase are also downregulated by dexamethasone treatment in AT. Of note, an impaired mitochondrial metabolism has been shown as a result of increased ROS production related to insulin resistance (3) .
Limitations of the study. This study has several limitations. First, the small number of subjects investigated poses a statistical power challenge, particularly for the AT analyses. The amount of tissue sampled is one of the difficulties of in vivo studies in humans, especially concerning AT from lean subjects. Here, we chose to carefully select high-quality RNA and gene profiling data combined with appropriate statistical analyses to provide as much confident results as possible. However, the AT analyses suffer from a lack of power. Second, as the knowledge documented here was built from in vivo investigations we cannot exclude the possibility that the observations reported here may also arise from indirect effects through the regulation of factors involved in transcription or cross talk with other steroid hormone signaling. As a corollary, mineralocorticoid receptors that exhibit the same affinity for aldosterone and GC hormones may be activated with consequent proinflammatory effects on gene expression as recently described in rodent adipocytes (15) . Third, the data are built from tissue biopsies and thus do not account for anatomical tissue distribution or specific cell types such as SM fiber type or AT adipose or any other cell type. Furthermore, this study was designed with healthy male volunteers. Hence, inference to women or obese individuals is questionable. Finally, measurements were made at a single and quite short-term time point, which may not allow for identification of regulated pathways during long-term treatment or counterregulatory phenomenon that would be better elucidated via longitudinal profiling of subjects.
To conclude, the steroid treatment had an early deleterious impact on systemic inflammatory status and insulin sensitivity. Both SM and AT share common stress and inflammatory responses, even if there are different genes that enriched those functions, regarding the tissues. It is counterintuitive to find that the expression of some proteins involved in innate immunity was not blunted by GC but actually increased. Such an effect has been previously documented in human immune cells (12) and recently in ex vivo cultured human adipose tissue (23) . The proinflammatory signature within both tissues and the downregulation of 11BHSD1, which controls local production of cortisol in AT, can be accounted for as a global response to the rise in GC. We propose that GC may also increase the manifestations of an acute-phase response as a quick reaction to stress. Although the effects described here result both from direct and indirect impacts of GC, such in vivo studies are representative of per os GC therapies. The knowledge of the dexamethasone-responsive genes in adipose tissue and skeletal muscle could help to find novel drugs lacking side-effects on these target tissue.
